Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 57 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: ccRCC Clear all
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
HC-7366, Belzutifan
Drug
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Translocation Renal Cell Carcinoma
Interventions
Abemaciclib, Cabozantinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Baltimore, Maryland • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced May 21, 2026, 7:15 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Belzutifan, Pembrolizumab, Placebo
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
37
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Interventions
Casdatifan, Cabozantinib, Placebo
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
720 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
40
States / cities
Gilbert, Arizona • Goodyear, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ABBV-CLS-579, PD-1 inhibitor, VEGFR TKI
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
5
States / cities
Springdale, Arkansas • New Haven, Connecticut • Fort Wayne, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumor
Interventions
PLN-101095, Pembrolizumab
Drug
Lead sponsor
Pliant Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
6
States / cities
New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 21, 2026, 7:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Solid Tumor, Clear Cell Renal Cell Carcinoma, TNBC - Triple-Negative Breast Cancer, Colorectal Cancer, CRC, RCC, ccRCC
Interventions
CB-839, Talazoparib
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2022 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Metastatic Renal Cancer, Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer, Translocation Renal Cell Carcinoma
Interventions
Sasanlimab, Palbociclib, Axitinib
Drug
Lead sponsor
Stephanie Berg
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced May 21, 2026, 7:15 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms, Renal Cancer, Renal Neoplasms, Recurrent Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Neoplasms, Carcinoma, Renal Cell, Neoplasms, Glandular and Epithelial, Neoplasm by Histology, Adenocarcinoma, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms by Site, Kidney Diseases, Urologic Diseases
Interventions
NKT2152, palbociclib, sasanlimab
Drug · Other
Lead sponsor
NiKang Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
8
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma, Neuroendocrine Tumors, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma
Interventions
NN3201
Drug
Lead sponsor
Novelty Nobility, Inc.
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced May 21, 2026, 7:15 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer, Renal Cancer, Renal Cell Carcinoma, Renal Cell Cancer Metastatic, Renal Cell Carcinoma Recurrent, Renal Cell Cancer, Recurrent, Kidney
Interventions
Belzutifan, Cabozantinib
Drug
Lead sponsor
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
10
States / cities
Los Angeles, California • Miami, Florida • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced May 21, 2026, 7:15 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma
Interventions
Volrustomig, Casdatifan, Nivolumab, Ipilimumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
1,116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
7
States / cities
La Jolla, California • Aurora, Colorado • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma, Clear Cell Renal Cell Cancer (ccRCC), Squamous Cell Non Small Cell Lung Cancer
Interventions
GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib, GI-101A
Drug
Lead sponsor
GI Innovation, Inc.
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
New York, New York • Huntersville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 7:15 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
Interventions
Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan, Computerized tomography (CT) Scan
Drug · Radiation · Procedure
Lead sponsor
Kelly Fitzgerald, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced May 21, 2026, 7:15 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors
Interventions
zanzalintinib, AB521, Nivolumab
Drug · Biological
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
14
States / cities
Los Angeles, California • Miami, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer
Interventions
124-Iodine-cG250 (124I-cG250), CT
Drug · Procedure
Lead sponsor
Heidelberg Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Los Angeles, California • Stanford, California • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced May 21, 2026, 7:15 PM EDT
Withdrawn Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
piflufolastat F 18
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
St Louis, Missouri • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced May 21, 2026, 7:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
Interventions
CB-839, Nivolumab
Drug
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Scottsdale, Arizona • Palo Alto, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced May 21, 2026, 7:15 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Kidney Cancer
Interventions
177Lu-PSMA-617
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced May 21, 2026, 7:15 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Interventions
MDX-1203
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 21, 2013 · Synced May 21, 2026, 7:15 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
33
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
BMS-986506
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC)
Interventions
Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
1,314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
46
States / cities
Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced May 21, 2026, 7:15 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer, Non-Small Cell Lung Cancer Squamous, Non-Small Cell Lung Cancer Non-squamous, Colorectal Cancer (MSI-H), Gastric Cancer, Cervical Cancer, Basal Cell Carcinoma, Bladder Cancer, Merkel Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Cutaneous Squamous Cell Carcinoma, Pleural Mesothelioma, Esophageal Cancer, Endometrial Carcinoma, Solid Tumor, Solid Tumor, Adult, MSI-H Solid Malignant Tumor, Cancer With A High Tumor Mutational Burden, Epithelial Ovarian Carcinoma, Primary Peritoneal Cancer, Gastroesophageal Junction (GEJ) Cancer, Acral Melanoma, Mucosal Melanoma, Cutaneous Melanoma, DMMR Solid Malignant Tumor, Fallopian Tube Cancer, Ovarian Cancer, MSI-H Cancer, DMMR Cancer, Pancreas Adenocarcinoma (MSI-H), Skin Cancer, Viral Cancer, Cervical Cancers, Endometrial Cancer
Interventions
MDNA11, Pembrolizumab (KEYTRUDA®)
Drug
Lead sponsor
Medicenna Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
7
States / cities
San Diego, California • San Francisco, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced May 21, 2026, 7:15 PM EDT